Atara Biotherapeutics is a leading cell therapy company developing products for patients with cancer and multiple sclerosis (MS). The company was founded in 2012 and named after Atara Ciechanover who suffered from cancer before passing away.
Originating from over a decade of groundbreaking clinical experience at Memorial Sloan Kettering and QIMR Berghofer, Atara’s T-cell immunotherapies are precisely designed to recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells. Our “Off-the-Shelf”, or allogeneic, T-cells are engineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment.
Atara’s most advanced T-cell immunotherapy in development, ATA129, is a treatment for cancer patients with rituximab refractory Epstein-Barr virus (EBV) associated Post-Transplant Lymphoproliferative Disease (EBV-PTLD) as well as other EBV positive hematologic and solid tumors including nasopharyngeal carcinoma (NPC). Phase 3 studies of ATA129 in EBV-PTLD are expected to start in 2017 and a Phase 1/2 study in NPC is planned for 2018. In addition, Atara expects to submit ATA129 for conditional marketing authorization in the EU in 2018.
The company’s next generation T-cell immunotherapy for autoimmune disease, or ATA188, selectively targets specific antigens of EBV believed to be important for the potential treatment of multiple sclerosis (MS). The Atara clinical pipeline also includes allogeneic T-cell immunotherapies targeting Wilms Tumor 1 (WT1), or ATA520, and Cytomegalovirus (CMV), or ATA230.